Drug Price Trends for BUDESONIDE EC

Average Pharmacy Cost for BUDESONIDE EC

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BUDESONIDE EC 3 MG CAPSULE	65162-0778-10	0.54762	EACH	2025-04-23
BUDESONIDE EC 3 MG CAPSULE	51862-0580-01	0.54762	EACH	2025-04-23
BUDESONIDE EC 3 MG CAPSULE	65162-0778-10	0.53566	EACH	2025-03-19
BUDESONIDE EC 3 MG CAPSULE	51862-0580-01	0.53566	EACH	2025-03-19
BUDESONIDE EC 3 MG CAPSULE	65162-0778-10	0.51172	EACH	2025-02-19

Market Analysis and Price Projections for Budesonide EC

Introduction to Budesonide EC

Budesonide EC, a member of the glucocorticoids drug class, is widely used for treating various conditions including asthma, chronic obstructive pulmonary disease (COPD), Crohn's disease, and ulcerative colitis. Here, we will delve into the market dynamics, growth drivers, and price projections for budesonide EC.

Market Size and Growth

The global budesonide market is experiencing significant growth, driven by several key factors. As of 2025, the market size is valued at USD 8,731.3 million and is projected to reach USD 15,208.9 million by 2033, with a Compound Annual Growth Rate (CAGR) of 5.6% during the forecast period[1].

Key Drivers of Growth

Increasing Prevalence of Chronic Diseases

The rising prevalence of asthma, COPD, and inflammatory bowel disease (IBD) globally is a major driver of the budesonide market. For instance, in the U.S., 8.4% of adults and 5.8% of children under 18 have been diagnosed with asthma, contributing significantly to the demand for budesonide[3].

Growing Awareness and Diagnostic Techniques

Public health campaigns and improved diagnostic techniques are increasing patient awareness and diagnosis rates of respiratory and gastrointestinal disorders. This heightened awareness is driving broader adoption of budesonide[1].

Technological Advancements

Improved delivery systems and novel formulations are enhancing drug efficacy and reducing side effects. These technological advancements are crucial in maintaining the market's growth momentum[1].

Expansion into Emerging Markets

Growing healthcare spending and rising disease prevalence in developing countries, particularly in the Asia Pacific region, present significant growth opportunities for budesonide. China, with its large population and increasing healthcare expenditure, is a key market driver[3].

Regional Market Dynamics

Asia Pacific Dominance

The Asia Pacific region, led by China, is the largest market for budesonide and is expected to continue growing at a substantial CAGR. The region's large population and increasing healthcare spending are key factors contributing to this growth[3].

U.S. Market

In the U.S., the increasing prevalence of COPD and asthma is expected to boost the growth of the budesonide market. According to the CDC, 5.0% of the U.S. population has been diagnosed with COPD, and 8.4% of adults have asthma, which are significant market drivers[3].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the budesonide market:

Increased Demand

The pandemic has led to an increased demand for budesonide due to its use in treating respiratory illnesses. A study by the University of Oxford found that early treatment with inhaled budesonide shortens recovery time in non-hospitalized COVID-19 patients[3].

Production and Supply Chain Disruptions

However, the pandemic has also caused production and supply chain disruptions, affecting the availability of raw materials and limiting workforce operations, which has moderately affected the industry's growth[1].

Price Projections and Cost Analysis

Current Pricing

The cost for budesonide EC varies depending on the formulation and dosage. For example:

• Oral Delayed Release Capsule: The cost for Entocort EC 3 mg oral delayed release capsule is around $92 for a supply of 10 capsules[2].
• Inhalation Suspension: The cost for budesonide (0.5 mg/2 mL) inhalation suspension is around $76 for a supply of 60 milliliters[5].

Generic Versions and Price Impact

The emergence of generic versions of budesonide has expanded the market and is expected to drive market growth. Generic versions are generally more affordable, with prices such as $98.98 for 20 capsules of budesonide oral delayed release capsules[2].

Future Pricing Trends

Given the projected market growth and the increasing demand for budesonide, prices are likely to remain competitive. However, technological advancements and the development of new formulations could lead to slight price increases. The overall trend suggests that while prices may fluctuate, the availability of generic versions will help keep costs manageable for patients.

Key Players and Market Strategies

Major players in the budesonide market include AstraZeneca, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz, Dr. Falk Pharma, Chiesi Farmaceutici, Orion, Cipla, Synmosa Biopharma, Lunan Better Pharmaceutical, and Shanghai Sine Promod Pharmaceutical. These companies are focusing on developing new products, expanding their geographical reach, and entering into strategic partnerships to strengthen their market position[1].

Future Outlook

The budesonide market is poised for continued growth driven by the increasing prevalence of respiratory diseases, strong healthcare infrastructure, and favourable reimbursement policies. The emergence of generic versions and technological advancements in the medical industry are expected to offer further growth opportunities.

Expansion of Therapeutic Applications

Budesonide's efficacy in treating a wide range of conditions, including allergic rhinitis and ulcerative colitis, is driving broader adoption. This expansion in therapeutic applications is expected to continue, further boosting market growth[1].

Regulatory and Developmental Activities

Regulatory milestones and developmental activities, such as the approval of new formulations and the launch of late-stage emerging therapies, will significantly impact the market. These activities will provide the current development scenario of budesonide and support clients in their decision-making processes regarding their therapeutic portfolios[4].

Key Takeaways

• Market Growth: The global budesonide market is projected to grow from USD 8,731.3 million in 2025 to USD 15,208.9 million by 2033.
• Regional Dominance: The Asia Pacific region, particularly China, is the largest market and is expected to grow substantially.
• Key Drivers: Increasing prevalence of chronic diseases, growing awareness of respiratory and gastrointestinal disorders, technological advancements, and expansion into emerging markets.
• Price Trends: Prices are expected to remain competitive with the availability of generic versions.
• Future Outlook: Continued growth driven by increasing disease prevalence, strong healthcare infrastructure, and favourable reimbursement policies.

FAQs

What is the projected market size of the budesonide market by 2033?

The budesonide market is expected to reach USD 15,208.9 million by 2033[1].

What is the CAGR of the budesonide market over the forecast period?

The budesonide market is expected to exhibit a CAGR of 5.6% over the forecast period[1].

Which region dominates the budesonide market?

The Asia Pacific region, particularly China, dominates the budesonide market and is expected to grow at a substantial CAGR[3].

What are the key drivers of the budesonide market?

Key drivers include the increasing prevalence of asthma and COPD, growing awareness of respiratory and gastrointestinal disorders, technological advancements, and expansion into emerging markets[1][3].

How has the COVID-19 pandemic affected the budesonide market?

The pandemic has increased demand for budesonide due to its use in treating respiratory illnesses but has also caused production and supply chain disruptions[1][3].

Sources

1. Strategic Analysis of Budesonide (BUD) Market Growth 2025-2033 - Data Insights Market
2. Entocort EC Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. Generic BUDESONIDE INN equivalents, drug patent expiry and ... - Drug Patent Watch
4. Budesonide Market Size, Forecast, and Drug Insight - 2032 - Research and Markets
5. Budesonide Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com

Last updated: 2025-01-02